Figure 2.
Differences in survival rates between high and low ASF1B expression groups. (A–C) Low expression of ASF1B predicts a good prognosis in stomach adenocarcinoma (STAD), including overall survival (OS), progression-free survival (PFS), and first progression (FP). (D) ASF1B was also associated with poor OS from the STAD tissues we collected. ASF1B = anti-silencing function 1B.
